This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today

Dow Jones

01/16

ImmunityBio stock is on a tear in 2026 and it looks like the biotech company's stellar rally will keep going.

The shares are up 99% this year, as of Thursday close. In fact, they've climbed on every trading day so far in 2026. The streak, and the impressive gain, are set to continue as the stock was pointing another 21% higher ahead of the open Friday.

The catalysts also keep coming. The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday. Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.

Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a 163% upside to Thursday's closing price.

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2603967590"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603967590\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603967590?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603967590","market":"sh","top_or_hot":-1,"title":"This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today","media":"Dow Jones","content":"<html><head></head><body><p>ImmunityBio stock is on a tear in 2026 and it looks like the biotech company&#39;s stellar rally will keep going.</p><p>The shares are up 99% this year, as of Thursday close. In fact, they&#39;ve climbed on every trading day so far in 2026. The streak, and the impressive gain, are set to continue as the stock was pointing another 21% higher ahead of the open Friday.</p><p>The catalysts also keep coming. The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday. Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.</p><p>Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a 163% upside to Thursday&#39;s closing price.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-16 19:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>ImmunityBio stock is on a tear in 2026 and it looks like the biotech company&#39;s stellar rally will keep going.</p><p>The shares are up 99% this year, as of Thursday close. In fact, they&#39;ve climbed on every trading day so far in 2026. The streak, and the impressive gain, are set to continue as the stock was pointing another 21% higher ahead of the open Friday.</p><p>The catalysts also keep coming. The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday. Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.</p><p>Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a 163% upside to Thursday&#39;s closing price.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603967590","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603967590","pubTimestamp":1768562891,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ImmunityBio stock is on a tear in 2026 and it looks like the biotech company's stellar rally will keep going.The shares are up 99% this year, as of Thursday close. In fact, they've climbed on every trading day so far in 2026. The streak, and the impressive gain, are set to continue as the stock was pointing another 21% higher ahead of the open Friday.The catalysts also keep coming. The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday. Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a 163% upside to Thursday's closing price.This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc."},"translate_title":"这只生物科技股今年上涨了100%。为什么今天又飙升了。——Barrons.com","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"ImmunityBio stock is on a tear in 2026 and it looks like the biotech company's stellar rally will keep going.The shares are up 99% this year, as of Thursday close. In fact, they've climbed on every trading day so far in 2026. The streak, and the impressive gain, are set to continue as the stock was pointing another 21% higher ahead of the open Friday.The catalysts also keep coming. The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday. Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a 163% upside to Thursday's closing price.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}